Completed Strategic Leadership and Operational Transformation from R&D to Commercial OperationsRebranded as Dyadic Applied BioSolutions to Reflect Our New Operational PrioritiesFull Redesign of Corporate Website to Prioritize Commercial Execution and Long-term Value CreationCompleted $5.3 million Equity Offering to Strengthen Liquidity and Help Fund Pipeline and Commercial GrowthAchieved Key Development and Commercial Milestones in Life Sciences and Nutrition MarketsAdvanced Multiple Recombinant Protein Pro ...

Company Overview - Dyadic is a bioprocessing platform company transitioning from R&D to commercial revenue generation[4, 10, 24] - The company has two validated platforms, C1 and Dapibus, targeting life sciences, food/nutrition, and bio-industrial markets[4, 24] - Dyadic's market capitalization is $3009 million as of July 21, 2025, with approximately $74 million in cash and investment-grade securities as of March 31, 2025[62] Market Opportunity - The company is targeting a $25 billion+ market opportunity across key segments[7, 62] - The recombinant food & nutrition market is estimated at ~$11 billion in 2025[16, 31] - The cell culture media market is estimated at ~$5 billion in 2025, while the molecular biology reagents market is estimated at ~$2 billion in 2025[25, 27] - The recombinant bio-industrial enzymes market is estimated at ~$6 billion in 2025[16, 36] Commercial Strategy - Dyadic is focused on non-therapeutic applications for near-term revenue generation[4, 20, 62] - The company utilizes three revenue pathways: strain licensing, strategic partnerships, and direct product sales[42] - Initial revenue streams are active, with multiple non-therapeutic protein products expected to launch over the next 12-36 months[7, 24]

DNase I Oncology Platform - The company is focused on advancing its proprietary DNase I technology platform to address multiple high-value cancer indications[2, 5] - DNase I targets Neutrophil Extracellular Traps (NETs) to improve immunotherapies and chemotherapies[2, 5] - DNase I digests both double and single-stranded DNA, as well as DNA:RNA hybrids, exposing cancer cells to the immune system and reducing therapy resistance[6] - Systemic administration of DNase I improves the efficacy of PD-1 blockade, resulting in the lowest tumor volume growth compared to either DNase I or anti-PD-1 alone[19] Pipeline and Clinical Development - The company's lead program, XBIO-015, combines systemic DNase I with chemotherapy for pancreatic carcinoma[7] - A Phase 1 study is planned, featuring dose escalation and expansion in subjects with locally advanced or metastatic solid tumors, with pancreatic cancer and other solid tumor indications[2, 40] - The company believes that an ORR greater than 50% or PFS greater than 9 months would be a meaningful improvement to the current standard of care for pancreatic cancer[45] Market Opportunity - The company is initially targeting pancreatic carcinoma, a multi-billion-dollar indication with significant unmet need, with a projected market of $48 billion by 2025[2, 39] - Approximately 62,000 people are diagnosed with pancreatic cancer annually, and approximately 50,000 die from it annually[39] - There were approximately 19 million new solid tumor cases in the U S in 2022, leading to approximately 6 million solid tumor-related deaths[46] Collaboration and Intellectual Property - The company is collaborating with VolitionRX to develop proprietary adoptive cell therapies potentially targeting multiple solid cancer types[2, 58] - VolitionRX is expected to fund the research program, with both parties sharing proceeds from commercialization or licensing of any resulting products[60] - The company has an IP portfolio covering the co-administration of Systemic DNase I with ICIs, radiation, and chemo, as well as DNase I for pancreatic cancer and DNase I-secreting CAR T cells[62, 64]